2016
DOI: 10.1186/s12895-016-0046-1
|View full text |Cite
|
Sign up to set email alerts
|

Effect of 12-O-tetradecanoylphorbol-13-acetate-induced psoriasis-like skin lesions on systemic inflammation and atherosclerosis in hypercholesterolaemic apolipoprotein E deficient mice

Abstract: BackgroundRisk of cardiovascular disease is increased in patients with psoriasis, but molecular mechanisms linking the two conditions have not been clearly established. Lack of appropriate animal models has hampered generation of new knowledge in this area of research and we therefore sought to develop an animal model with combined atherosclerosis and psoriasis-like skin inflammation.MethodsTopical 12-O-tetradecanoylphorbol-13-acetate (TPA) was applied to the ears twice per week for 8 weeks in atherosclerosis-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
20
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(22 citation statements)
references
References 37 publications
2
20
0
Order By: Relevance
“…ApoE À/À mice cutaneous lipids were excessive accumulation in which pathological changes of psoriasis corneum changed as dyslipideamia [13,14]. Recently, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ApoE À/À mice were reported, which might evoke systemic immune-inflammatory effects and question the role of psoriasis induced inflammation in the pathogenesis of atherosclerosis in psoriatic patients [15]. Based on the critical role of IL-23/ Th17 axis in psoriasis, topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, could induce closely resembling human plaque-type psoriasis [16].…”
Section: Introductionmentioning
confidence: 99%
“…ApoE À/À mice cutaneous lipids were excessive accumulation in which pathological changes of psoriasis corneum changed as dyslipideamia [13,14]. Recently, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ApoE À/À mice were reported, which might evoke systemic immune-inflammatory effects and question the role of psoriasis induced inflammation in the pathogenesis of atherosclerosis in psoriatic patients [15]. Based on the critical role of IL-23/ Th17 axis in psoriasis, topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, could induce closely resembling human plaque-type psoriasis [16].…”
Section: Introductionmentioning
confidence: 99%
“…[ 32 ] In this study, “white” skin patches at similar position in the back skin were used for analysis as different hair cycles can influence the skin response to compounds and even the development of inflammation. [ 25,33 ] The SC in these “white” back skin patches of hairy mice has fewer number of corneocyte layers as compared to ear skin. The back skin of nude mice with a larger interfollicular area displays a thicker SC with more corneocyte layers, [ 34 ] suggesting that the reduced number of corneocyte layers in hairy mice is a direct effect of the presence of dense hair follicles and/or fur.…”
Section: Discussionmentioning
confidence: 99%
“…APOE −/− mice and other hypercholesterolaemic mouse models have recently been used to study the relation between psoriasis and the comorbidities dyslipidemia and atherosclerosis. [ 23‐25 ] Differential effects on the aggravation of dyslipidemia in APOE −/− mice have been described in response to the induction of psoriasis‐like skin inflammation by topical application of compounds on ear vs back skin, with back skin being more effective. [ 6,26 ] As lipids play a major role in the skin barrier, it is crucial to know whether there are differences in lipid barrier in ear vs back skin of APOE −/− mice.…”
Section: Introductionmentioning
confidence: 92%
“…An anti-inflammatory activity study of the SBKT was performed using the λ-Carrageenan-stimulated Wistar rat inflammation model and the TPA-stimulated CD-1 mice psoriasis-like model. The TPA-stimulated CD-1 mice psoriasis-like model is well-established for studying the disease-modulating efficacy of test compounds (Madsen et al, 2016; Ma et al, 2018; Yang et al, 2018). Treatment of the Carrageenan-stimulated Wistar rats with a human equivalent dose of SBKT showed a significant decrease in the drug-induced paw volume increase and edema in the rats.…”
Section: Discussionmentioning
confidence: 99%